Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Active not recruiting 7Completed 4Recruiting 3Terminated 2Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Head & Neck 2Genitourinary 2Dermatologic 2Other solid neoplasm 1Gynecologic 1Gastrointestinal 1

Conditions

Carcinoma, Non-Small-Cell Lung 78Melanoma 51Squamous Cell Carcinoma of Head and Neck 40Neoplasm Metastasis 30Neoplasms 27Breast Neoplasms 26Colorectal Neoplasms 23Carcinoma, Renal Cell 23Head and Neck Neoplasms 21Triple Negative Breast Neoplasms 20Carcinoma, Transitional Cell 20Stomach Neoplasms 19Ovarian Neoplasms 17Lung Neoplasms 15Uterine Cervical Neoplasms 12Esophageal Neoplasms 12Carcinoma, Hepatocellular 12Urinary Bladder Neoplasms 11Parkinson Disease 4, Autosomal Dominant Lewy Body 11Pancreatic Neoplasms 10Small Cell Lung Carcinoma 9Multiple Myeloma 9Recurrence 8Endometrial Neoplasms 8Carcinoma, Merkel Cell 8Lymphoma, Non-Hodgkin 7Lymphoma 7Skin Neoplasms 6Mesothelioma 6Hodgkin Disease 6

Interventions

Cisplatin 4Radiotherapy, Intensity-Modulated 3Radiotherapy 3pembrolizumab 2Cetuximab 2Biopsy 2utomilumab 1tremelimumab 1motexafin gadolinium 1durvalumab 1antineoplaston AS 2-1 1antineoplaston A10 1Surveys and Questionnaires 1Surgical Procedures, Operative 1Radiosurgery 1Radiation 1Platinum 1Observation 1Nivolumab 1Ipilimumab 1Immunohistochemistry 1Immunoglobulin G 1Fluorouracil 1Fluorescent Antibody Technique 1Flow Cytometry 1Etoposide 1Electroacupuncture 1Drug Therapy 1Disulfides 1Diagnosis, Oral 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × Oropharyngeal Neoplasms × pembrolizumab × Clear all
NCT04301011 2025-04-23

RAPTOR

Turnstone Biologics, Corp.

Phase 1 Terminated
27 enrolled
DermatologicGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Mesothelioma, Oropharyngeal Neoplasms, Skin Neoplasms

NCT03809624 2024-10-23

PDL1x41BB

Inhibrx Biosciences, Inc

Phase 1 Terminated
160 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Adenocarcinoma Of Esophagus, Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Oropharyngeal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡